共 50 条
- [31] A prognostic predictive model based on the correlation of standard clinicopathologic characteristics with oncotype Dx 21-gene recurrence score for node-negative and ER positive breast cancerCANCER RESEARCH, 2018, 78 (04)Mankbadi, Michael R.Luo, YiYasin, MadihaBen Khallouq, BerthaMoroose, Rebecca
- [32] Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC StudyJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) : 1829 - 1834Dowsett, MitchCuzick, JackWale, ChristopherForbes, JohnMallon, Elizabeth A.Salter, JanineQuinn, EmmaDunbier, AnitaBaum, MichaelBuzdar, AmanHowell, AnthonyBugarini, RobertoBaehner, Frederick L.Shak, Steven
- [33] Impact of the 21-Gene Recurrence Score Assay Compared With Standard Clinicopathologic Guidelines in Adjuvant Therapy Selection for Node-Negative, Estrogen Receptor-Positive Breast CancerANNALS OF SURGICAL ONCOLOGY, 2011, 18 (12) : 3399 - 3406Partin, Jessica F.Mamounas, Eleftherios P.
- [34] Impact of the 21-Gene Recurrence Score Assay Compared With Standard Clinicopathologic Guidelines in Adjuvant Therapy Selection for Node-Negative, Estrogen Receptor-Positive Breast CancerAnnals of Surgical Oncology, 2011, 18 : 3399 - 3406Jessica F. PartinEleftherios P. Mamounas
- [36] 21-gene recurrence score assay as a predictor of pathological response in neoadjuvant chemotherapy administration for ER-positive/HER2-negative early-stage breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Morales Murillo, SerafinGasol Cudos, AriadnaRodriguez, AlvaroCanosa Morales, CarlesMele Olive, JordiVilardell, FelipSanchez Guzman, Douglas
- [37] The 21-gene Recurrence® (RS) Score assay in estrogen receptor positive node negative breast cancer: Real-world chemotherapy usage and patient characteristics within the intermediate and high-risk RS categoryCANCER RESEARCH, 2019, 79 (04)Le, D.Chia, S.Simmons, C.Speers, C.Gondara, L.Nichol, A.Lohrisch, C.Gelmon, K. A.
- [38] Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER plus ) node-negative breast cancerANNALS OF ONCOLOGY, 2012, 23 (03) : 625 - 631Albanell, J.Gonzalez, A.Ruiz-Borrego, M.Alba, E.Garcia-Saenz, J. A.Corominas, J. M.Burgues, O.Furio, V.Rojo, A.Palacios, J.Bermejo, B.Martinez-Garcia, M.Limon, M. L.Munoz, A. S.Martin, M.Tusquets, I.Rojo, F.Colomer, R.Faull, I.Lluch, A.
- [39] Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx StudyCANCERS, 2023, 15 (05)Llombart-Cussac, AntonioAnton-Torres, AntonioRojas, BeatrizAndres, RaquelMartinez, NoeliaRodriguez, Cesar A.Marin, SaraPuertolas, TeresaGonzalez, Alejandro FalconFernandez-Murga, Maria LeonorHagen, CarlosRuiz-Borrego, Manuel
- [40] Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancerJOURNAL OF CLINICAL PATHOLOGY, 2015, 68 (10) : 839 - 843Vera-Badillo, Francisco E.Chang, Martin C.Kuruzar, GordanaOcana, AlbertoTempleton, Arnoud J.Seruga, BostjanGoldstein, RobynBedard, Philippe L.Tannock, Ian F.Amir, Eitan